424B5 filed Sep 10, 2026 at 16:56 ET
Axogen is conducting a $208.7M underwritten public offering of 4.91M shares at $42.50/share (a ~10% discount to the $47.27 close), with an underwriter option for an additional 736,500 shares. Net proceeds of ~$195.5M are earmarked to fund the $200M cash acquisition of BioCircuit Technologies (NerveTape/ConformaWrap products), expected to close in Q4 2026. The offering is not contingent on the acquisition closing. Existing shareholders face immediate dilution of $34.92/share (82% of offering price). The combination of a dilutive equity offering tied to a transformative acquisition creates a mixed signal, the acquisition expands the product portfolio but the 9.1% share increase and 10% discount to market are near-term headwinds.